Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide

There has been a steadily growing armamentarium of drugs for the symptomatic treatment of Parkinson's disease (PD). Consequently, as various various pharmaceutical agents are used, it has become more difficult to perform and compare clinical trials with different medication regimens. Given that levodopa remains the gold standard treatment, conversion factors have been proposed to calculate l-dopa equivalent doses (LEDs) for each drug to facilitate comparison of medication regimens. Adding up LEDs of each drug leads to a daily total LED that is artificial but feasible and—if used as a standard scheme—comparable internationally. Since the last widely accepted proposal of LEDs for PD drugs by Tomlinson et al.,1 there has been no update. We hereby propose LED conversion factors for opicapone and safinamide, which are currently missing, but urgently needed, in ongoing clinical trials and observational studies. Opicapone is a new peripheral catechol-O-methyl transferase (COMT) inhibitor. Tomlinson et al. have proposed a conversion ratio, rather than a conversion factor, for inhibitors of COMT activity, by considering the mode of action of these drugs in terms of prolongation of the duration of the coadministered l-dopa treatment. The suggested ratio for entacapone is 0.33 × LD (coadministered l-dopa dose); the suggested ratio for tolcapone is LD × 0.5, respectively.1 For opicapone, we suggest a ratio higher than for entacapone, given that our literature search (see Supporting Information S1) and clinical experience suggest that opicapone is slightly more efficacious than entacapone.2 However, there are no intriguing data suggesting that opicapone might be more efficient than tolcapone3; we therefore propose using the same ratio for calculating the LED of opicapone as is used for tolcapone (LD × 0.5). Safinamide is mainly a reversible monoamine oxidase-B (MAO-B) inhibitor. Other proposed mechanisms likely play no relevant additional role concerning l-dopa equivalence. For safinamide, we propose an LED of 100 mg, independently of the actual administered dose, given that full reversible inhibition of MAO-B activity is already reached in the lowest commercially available preparations of safinamide.4 In the previous scheme,1 this would make safinamide equivalent to 1 mg of rasagiline and 10 mg of oral selegiline. All existing LED proposals (including our current additions) are based on clinical experience and empirical approaches. They pooled together studies by individual researchers, which provided sparse and inconsistent data. Consequently, these proposals are neither objective nor inherently scientific. To the best of our knowledge, there has not been a thorough evaluation so far. There needs to be a critical retrospective discussion on whether calculating LED reflects what we ought to measure and whether conclusions drawn from these calculations are valid. This pseudo-validity remains the major limitation of calculating LEDs. In conclusion, we believe that our proposed conversions fit reasonably well into the previous scheme of conversion factors (Table 1) and still sufficiently reflect the potential of both drugs. However, they follow the same limitations as the previous proposals.1 Prospectively, the LED conversion factor scheme needs a global reassessment with an attempt to use more objective measurements (using validated rating scales, adjusting for placebo, etc.) and thereby allowing the inclusion of new agents. We thank Anne-Marie Williams for language editing and formatting the manuscript. We thank Joaquim Ferreira for his valuable input and for reviewing an earlier version of the manuscript (including detailed results and conclusions of our literature search). (1) Research Project: A. Conception, B. Organization, C. Execution; (2) Manuscript: A. Writing of the First Draft, B. Review and Critique. S.S.: 1A, 1B, 1C, 2A, 2B B.M.: 1C, 2B C.T.: 1A, 2B Ethical Compliance Statement: The authors confirm that the approval of an institutional review board or patient consent was not required for this work. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Funding Sources and Conflicts of Interest: The authors report no sources of funding and no conflicts of interest. Financial Disclosures for previous 12 months: S.S. has received salaries from the EU Horizon 2020 research and innovation program under grant agreement No. 634821 and from the Deutsche Forschungsgemeinschaft (DFG) under grant agreement No. MO 2088/5-1. B.M. has received honoraria for consultancy from Roche, Biogen, UCB, and Sun Pharma Advanced Research Company. B.M. is a member of the executive steering committee of the Parkinson Progression Marker Initiative and PI of the Systemic Synuclein Sampling Study of the Michael J. Fox Foundation for Parkinson's Research and has received research funding from the Deutsche Forschungsgemeinschaft (DFG), EU (Horizon2020), Parkinson Fonds Deutschland, Deutsche Parkinson Vereinigung, and the Michael J. Fox Foundation for Parkinson's Research. C.T. has received honoraria for consultancy from Britannia and Roche and for educational lectures from UCB. She has received research grants from the Michael J. Fox Foundation for Parkinson's Research and the EU (Horizon2020). She holds patents for the treatment of dyskinesia in PD with oxycodone/naloxone and the PDSS-2 Scale as well as publishing royalties for a book for PD patients published in Schattauer Verlag, Germany, 2015. Supporting Information Material S1. Methods, results, and references for literature search. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.